SShhhhh...That scares Vonny, Larry and bb...
no worries boys and girls, go back to your day dreaming...the scary realitycheck2014 did not mean it that way...we all know PVCT MGT is doing there very very best they can.......gosh darn it, that is all that counts...do you want cookies and Kool-aid now?
LMAO....you may have inhaled a bit too deep before typing that....go easy, there is plenty of cannabis to go around
and news of their poster presentations drives SP nicely
Meanwhile, back at PVCT........ struggling to hold $1...promises pushed to Nov (we assume 2014, but investors have been fooled on that point for the past 4 years)
LOL...blocking patent are standard operating practice..it gives them control over future markets. Trust me, Pfizer is not worried about (or interested in) PV-10 getting to the market (or they would have purchased PVCT years ago, they are buying generic companies like crazy to secure low cost revenue streams)...but they might be interested in putting the breaks on a wasteful combination when more impactful options are available. The cost of the patent is budget dust for them.
BTW, since the patent was signed have you seen a combination pre-clinical or clinical trial emerge?
Do they advertise directly to patients...LMAO are you serious? Ever since formularies began to restrict access pharma companies have engaged DTC advertising to make their care....Larry, Larry, Larry.....what planet are you from?
head to head PIII for NRAS mutated melanoma patients is currently underway, they already have Novartis as a partner
And look at that, they have a second molecule selumetinib in development (3 phase III trials), will a partner (Astra Zeneca)
Meanwhile, back at PVCT.....
I count 4 unique 2014 ESMO posters from this group, one a "Best Poster" winner for Developmental Therapeutics Poster Session.
Meanwhile, back at PVCT...rehashed 4 year old data is offered as the exciting vista for the future....
Even Vonny is getting worried now
Creates the image of a hairy armed tattooed surgeon 'inking' their skin....of course, that was the story 4+ years ago...todays market is very different. PVCT data has not kept up
They know what the FDA wants, which is why the PIII is so delayed, and now of such narrow scope...non-metastatic, benign stage III patients. They are hard to find in a research or commercial setting
Yes, I was the one years ago saying the FDA would not give a green light to a PIII in stage III/IV patients after seeing the PII data....I was right. PVCT had to local control goal where patient risk is minimal. What is your point Larry?
SP is always "holding well"....$49 more to go...LMAO
ESMO presentations seems to be having a positive effect for MACK... solid evidence of forward progress
Meanwhile, back at PVCT........... they are still slicing old data and dreaming of tomorrow
Funny how those who do not see the light always seem to be able to present coherent analysis of the PVCT story, while those with dreams can only present their hopes and aspirations...why is that....
Hos is that ESMO bump going for PVCT?